Healthcare

CytoDyn to Prepare a Phase 3 Protocol to Submit to the FDA for a Three-Arm Comparative and Combination Trial of Leronlimab and Remdesivir

VANCOUVER, Washington, May 18, 2020 — Three arms of this trial will be leronlimab, remdesivir, and leronlimab + remdesivir CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), […]

Healthcare

CytoDyn (OTC: CYDY) to Offer No-Cost Exploratory Laboratory Testing for Childhood Inflammatory Disease Associated with COVID-19

VANCOUVER, Washington, May 15, 2020– CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced it is […]

Healthcare

Ajinomoto Bio-Pharma Services Announces Manufacturing Partnership with CytoDyn (OTC: CYDY) for Drug Product Used in COVID-19 Clinical Trials

SAN DIEGO, May 5, 2020  —- Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce it has entered into a manufacturing services agreement with CytoDyn Inc., […]

Healthcare

CytoDyn (OTC: CYDY) Reports Strong Results from eIND COVID-19 Patients Treated with Leronlimab; Majority of Patients Have Demonstrated Remarkable Recoveries

54 eINDs approved by FDA and 49 patients have been treated with leronlimab thus far VANCOUVER, Washington, Apr 30, 2020  — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab […]

Healthcare

CytoDyn (OTC: CYDY) Announces Vyrologix as Proprietary Name for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients in the United States

Company appoints Interim Chief Financial Officer VANCOUVER, Washington, Apr 27, 2020  — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for […]

Healthcare

CytoDyn (OTC: CYDY) Submits Completed Biologics License Application (BLA) to the FDA for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients

VANCOUVER, Washington, Apr 27, 2020  — During the FDA’s review period, the Company will dedicate all resources to ensure availability of leronlimab for COVID-19 patients; Cancer programs continue with positive results VANCOUVER, Washington, April 27, 2020 […]

Healthcare

CytoDyn (OTC: CYDY) So. California Patients Treated with Leronlimab for COVID-19 under Emergency IND: 4 Patients with Moderate Indications Removed from Oxygen; 3 Patients Discharged from Hospital; 1 Patient Scheduled for Discharge Today; 1 Patient with Severe Indications Discharged, for Total of 5 Patients Discharged

VANCOUVER, Washington, Apr 13, 2020  — More than 25 EINDs approved by FDA for leronlimab use in COVID-19 patients Phase 2 trial – As of last week, 12 patients enrolled from 2 sites; 3 more […]

Healthcare

CytoDyn (OTC: CYDY) First Two Patients Enrolled in Randomized Phase 2, COVID-19 Trial with Leronlimab; Five More Severely Ill COVID-19 Patients Treated Under Emergency IND and Two Patients Have Already Extubated

Fifteen (15) severely ill COVID-19 patients have been treated under an EIND; 7-day results from the first four patients are available and are very promising; 7-day results for the first 10 patients will be available […]

Healthcare

CytoDyn (OTC: CYDY) Completes Non-dilutive $15 Million Convertible Note Financing with Conversion Rate at $4.50 Per Share without Warrants

VANCOUVER, Washington, Mar 31, 2020  — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that […]

Healthcare

FDA Clears CytoDyn’s (OTC: CYDY) Phase 2 Randomized Trial to Treat Mild-to-Moderately Ill Coronavirus Patients with Leronlimab; Enrollment to Begin Immediately

VANCOUVER, Washington, March 31, 2020 — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the […]

Healthcare

(OTC: CYDY) Three Additional Patients with Severe COVID-19 Treated with Leronlimab in New York Medical Center Bringing the Total to 10 Patients

VANCOUVER, Washington, Mar 30, 2020 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that an […]

Healthcare

CytoDyn Files FDA-Suggested Modifications to IND and Protocol for Phase 2 Clinical Trial for COVID-19 Patients with Mild to Moderate Indications and a Second Randomized Protocol for All COVID-19 Patients in Severe Condition Will be Filed Next Week per FDA Recommendation

VANCOUVER, Washington, March 27, 2020  — CytoDyn Inc. (CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that, at the […]

Healthcare

(OTC: CYDY) Leronlimab Used in Seven Patients with Severe COVID-19 Demonstrated Promise with Two Intubated Patients in ICU, Removed from ICU and Extubated with Reduced Pulmonary Inflammation

IncellDx’s evaluation of test results from the first four patients suggests immunological benefit within three days following treatment with leronlimab on all four patients and lower level of cytokine storm, especially IL-6 and TNF-α, which […]